These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 23555694)

  • 21. Clinical Implications of Antiviral Resistance in Influenza.
    Li TC; Chan MC; Lee N
    Viruses; 2015 Sep; 7(9):4929-44. PubMed ID: 26389935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emergence of drug resistance: implications for antiviral control of pandemic influenza.
    Alexander ME; Bowman CS; Feng Z; Gardam M; Moghadas SM; Röst G; Wu J; Yan P
    Proc Biol Sci; 2007 Jul; 274(1619):1675-84. PubMed ID: 17507331
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiviral prophylaxis during pandemic influenza may increase drug resistance.
    Eichner M; Schwehm M; Duerr HP; Witschi M; Koch D; Brockmann SO; Vidondo B
    BMC Infect Dis; 2009 Jan; 9():4. PubMed ID: 19154598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Can treatment increase the epidemic size?
    Xiao Y; Brauer F; Moghadas SM
    J Math Biol; 2016 Jan; 72(1-2):343-61. PubMed ID: 25925242
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals.
    Ferguson NM; Mallett S; Jackson H; Roberts N; Ward P
    J Antimicrob Chemother; 2003 Apr; 51(4):977-90. PubMed ID: 12654752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modelling the emergence of influenza drug resistance: The roles of surface proteins, the immune response and antiviral mechanisms.
    Dobrovolny HM; Beauchemin CAA
    PLoS One; 2017; 12(7):e0180582. PubMed ID: 28700622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modelling the evolution of drug resistance in the presence of antiviral drugs.
    Wu J; Yan P; Archibald C
    BMC Public Health; 2007 Oct; 7():300. PubMed ID: 17953775
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Likely effectiveness of pharmaceutical and non-pharmaceutical interventions for mitigating influenza virus transmission in Mongolia.
    Bolton KJ; McCaw JM; Moss R; Morris RS; Wang S; Burma A; Darma B; Narangerel D; Nymadawa P; McVernon J
    Bull World Health Organ; 2012 Apr; 90(4):264-71. PubMed ID: 22511822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monitoring the fitness of antiviral-resistant influenza strains during an epidemic: a mathematical modelling study.
    Leung K; Lipsitch M; Yuen KY; Wu JT
    Lancet Infect Dis; 2017 Mar; 17(3):339-347. PubMed ID: 27914853
    [TBL] [Abstract][Full Text] [Related]  

  • 30. China's chicken farmers under fire for antiviral abuse.
    Cyranoski D
    Nature; 2005 Jun; 435(7045):1009. PubMed ID: 15973368
    [No Abstract]   [Full Text] [Related]  

  • 31. Intermittent treatment of severe influenza.
    Deecke L; Dobrovolny HM
    J Theor Biol; 2018 Apr; 442():129-138. PubMed ID: 29355540
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuraminidase inhibitor resistance in influenza: assessing the danger of its generation and spread.
    Handel A; Longini IM; Antia R
    PLoS Comput Biol; 2007 Dec; 3(12):e240. PubMed ID: 18069885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiviral resistance during pandemic influenza: implications for stockpiling and drug use.
    Arino J; Bowman CS; Moghadas SM
    BMC Infect Dis; 2009 Jan; 9():8. PubMed ID: 19161634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emergence of oseltamivir-resistant pandemic (H1N1) 2009 virus within 48 hours.
    Inoue M; Barkham T; Leo YS; Chan KP; Chow A; Wong CW; Tze Chuen Lee R; Maurer-Stroh S; Lin R; Lin C
    Emerg Infect Dis; 2010 Oct; 16(10):1633-6. PubMed ID: 20875299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiviral resistance in influenza viruses: laboratory testing.
    Laplante J; St George K
    Clin Lab Med; 2014 Jun; 34(2):387-408. PubMed ID: 24856534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antivirals Targeting the Surface Glycoproteins of Influenza Virus: Mechanisms of Action and Resistance.
    Bai Y; Jones JC; Wong SS; Zanin M
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33917376
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the Influenza Resistance Information Study.
    Lina B; Boucher C; Osterhaus A; Monto AS; Schutten M; Whitley RJ; Nguyen-Van-Tam JS
    Influenza Other Respir Viruses; 2018 Mar; 12(2):267-278. PubMed ID: 29265727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives.
    Hurt AC; Chotpitayasunondh T; Cox NJ; Daniels R; Fry AM; Gubareva LV; Hayden FG; Hui DS; Hungnes O; Lackenby A; Lim W; Meijer A; Penn C; Tashiro M; Uyeki TM; Zambon M;
    Lancet Infect Dis; 2012 Mar; 12(3):240-8. PubMed ID: 22186145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence of antiviral drug resistance markers among human influenza A viruses in the Eastern Mediterranean Region, 2005-2016.
    Moasser E; Moasser A; Zaraket H
    Infect Genet Evol; 2019 Jan; 67():60-66. PubMed ID: 30389548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Understanding the Impact of Resistance to Influenza Antivirals.
    Holmes EC; Hurt AC; Dobbie Z; Clinch B; Oxford JS; Piedra PA
    Clin Microbiol Rev; 2021 Mar; 34(2):. PubMed ID: 33568554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.